Cyclosporin-A Associated Malignancy

Overview

Journal Clin Ophthalmol

Publisher Dove Medical Press

Specialty Ophthalmology

Date 2009 Aug 12

PMID 19668519

Citations 20

Authors

Jonathan M Durnian

Rosalind M K Stewart

Richard Tatham

Mark Batterbury

Stephen B Kaye

Affiliations

Soon will be listed here.

Abstract

The use of cyclosporin is well established within the ophthalmology community, especially against sight threatening intraocular inflammation. It is well known however, that immunosuppression in general is a risk factor for the development of malignancy and numerous studies point to the risk imposed by cyclosporin. This article analyses and reviews all relevant studies with regard to the development of malignancy associated with the use of cyclosporin and extrapolates this into the ophthalmic setting. This is to enable clinicians to assess the risks in individual patients and to present a monitoring regime which can be used in patients undergoing cyclosporin treatment. The review is solely concerned with the risk of the development of malignancy following cyclosporin immunosuppression and not with any other adverse effect.

Citing Articles

The Many Faces of Immune Thrombocytopenia: Mechanisms, Therapies, and Clinical Challenges in Oncological Patients.

Kos M, Tomaka P, Mertowska P, Mertowski S, Wojnicka J, Blazewicz A J Clin Med. 2024; 13(22).

PMID: 39597882 PMC: 11594473. DOI: 10.3390/jcm13226738.

HNRNPA2B1 stabilizes NFATC3 levels to potentiate its combined actions with FOSL1 to mediate vasculogenic mimicry in GBM cells.

Wang H, Shi Y, Zhou X, Zhang L, Yang A, Zhou D Cell Biol Toxicol. 2024; 40(1):44.

PMID: 38862832 PMC: 11166796. DOI: 10.1007/s10565-024-09890-5.

Incidence, Risk Factors, and Outcomes of De Novo Malignancy following Kidney Transplantation.

Chukwu C, Wu H, Pullerits K, Garland S, Middleton R, Chinnadurai R J Clin Med. 2024; 13(7).

PMID: 38610636 PMC: 11012944. DOI: 10.3390/jcm13071872.

Unilateral conjunctival Classic Kaposi Sarcoma following a COVID 19 booster.

White E, Fazio N, Tourmouzis K, Ryu S, Finger P, Sassoon J Am J Ophthalmol Case Rep. 2024; 34:101986.

PMID: 38601193 PMC: 11004082. DOI: 10.1016/j.ajoc.2023.101986.

Neoplastic Progression of Barrett's Esophagus Among Organ Transplant Recipients: a Retrospective Cohort Study.

Patel V, Sanaka M, Qin Y, McMichael J, Bena J, Beveridge C J Gastrointest Surg. 2023; 27(9):1785-1793.

PMID: 37268829 DOI: 10.1007/s11605-023-05722-9.

References

Namyslowski G, Religa Z, Steszewska U, Misiollek M, Czecior E . [A case of laryngeal carcinoma as a result of immunosuppressive therapy with cyclosporin A following heart transplantation]. Otolaryngol Pol. 1994; 48(1):72-4. View

Nussenblatt R, Palestine A, Chan C . Cyclosporine therapy for uveitis: long-term followup. J Ocul Pharmacol. 1985; 1(4):369-82. DOI: 10.1089/jop.1985.1.369. View

Swoboda A, Fabrizii V . Tonsillar carcinoma in a renal graft recipient treated with cyclosporine A. Clin Nephrol. 1993; 39(5):272-4. View

Cockburn I, KRUPP P . The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun. 1989; 2(5):723-31. DOI: 10.1016/s0896-8411(89)80010-1. View

Dharnidharka V, Ho P, Stablein D, Harmon W, Tejani A . Mycophenolate, tacrolimus and post-transplant lymphoproliferative disorder: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant. 2002; 6(5):396-9. DOI: 10.1034/j.1399-3046.2002.00021.x. View

Boshoff C, Weiss R . Epidemiology and pathogenesis of Kaposi's sarcoma-associated herpesvirus. Philos Trans R Soc Lond B Biol Sci. 2001; 356(1408):517-34. PMC: 1088442. DOI: 10.1098/rstb.2000.0778. View

Suttorp-Schulten M, Rothova A . The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996; 80(9):844-8. PMC: 505625. DOI: 10.1136/bjo.80.9.844. View

Glover M, Deeks J, Raftery M, Cunningham J, Leigh I . Immunosuppression and risk of non-melanoma skin cancer in renal transplant recipients. Lancet. 1997; 349(9049):398. DOI: 10.1016/S0140-6736(97)80015-3. View

Borel J, Feurer C, GUBLER H, STAHELIN H . Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions. 1976; 6(4):468-75. DOI: 10.1007/BF01973261. View

10.

Borel J, Feurer C, Magnee C, STAHELIN H . Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977; 32(6):1017-25. PMC: 1445439. View

11.

Wakefield D, McCluskey P . Cyclosporine: a therapy in inflammatory eye disease. J Ocul Pharmacol. 1991; 7(3):221-6. View

12.

Piepkorn M, Kumasaka B, Krieger J, Burmer G . Development of human papillomavirus-associated Buschke-Löwenstein penile carcinoma during cyclosporine therapy for generalized pustular psoriasis. J Am Acad Dermatol. 1993; 29(2 Pt 2):321-5. DOI: 10.1016/0190-9622(93)70186-w. View

13.

. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005; 352(4):351-61. DOI: 10.1056/NEJMoa041884. View

14.

Young A, Rao S, Cheng L, Wong A, Leung A, Lam D . Combined intravenous pulse methylprednisolone and oral cyclosporine A in the treatment of corneal graft rejection: 5-year experience. Eye (Lond). 2002; 16(3):304-8. DOI: 10.1038/sj.eye.6700144. View

15.

Seshadri L, George S, Vasudevan B, Krishna S . Cervical intraepithelial neoplasia and human papilloma virus infection in renal transplant recipients. Indian J Cancer. 2003; 38(2-4):92-5. View

16.

Macarez R, Bossis S, Robinet A, Le Callonnec A, Charlin J, Colin J . Conjunctival epithelial neoplasias in organ transplant patients receiving cyclosporine therapy. Cornea. 1999; 18(4):495-7. DOI: 10.1097/00003226-199907000-00018. View

17.

Weinstein S, Orel S, Collazzo L, Conant E, Lawton T, Czerniecki B . Cyclosporin A-induced fibroadenomas of the breast: report of five cases. Radiology. 2001; 220(2):465-8. DOI: 10.1148/radiology.220.2.r01au45465. View

18.

Stallone G, Schena A, Infante B, Di Paolo S, Loverre A, Maggio G . Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med. 2005; 352(13):1317-23. DOI: 10.1056/NEJMoa042831. View

19.

Cherikh W, Kauffman H, McBride M, Maghirang J, Swinnen L, Hanto D . Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation. 2003; 76(9):1289-93. DOI: 10.1097/01.TP.0000100826.58738.2B. View

20.

Guba M, Graeb C, Jauch K, Geissler E . Pro- and anti-cancer effects of immunosuppressive agents used in organ transplantation. Transplantation. 2004; 77(12):1777-82. DOI: 10.1097/01.tp.0000120181.89206.54. View